-transparent.png){kind=logo}
The effects of two new non-peptide angiotensin receptor antagonists, irbesartan (SR 47436/BMS-186295, (2-n-butyl-4-spirocyclopentane-1-[((2'-tetrazol-5-yl)bipheny l-4-yl)methyl]2 - imidazolin-5-one) and SR 47155A (2-n-butyl-4-spirocyclopentane-1-[((2'-carboxy)biphenyl-4-yl)methy l]2- imidazolin-5-one, trifluoroacetate), on angiotensin II-induced pressor responses were studied in the pithed rat in comparison to losartan, EXP 3174 and [Sar1,Val5,Ala8]angiotensin II. SR 47155A (1-10 mg/kg i.v.) and losartan (1-10 mg/kg i.v.) shifted dose dependently the dose-response curve of angiotensin II to the right without affecting the maximal response. SR 47436 (0.3-10 mg/kg i.v.), EXP 3174 (0.03-1 mg/kg i.v.) and [Sar1,Val5,Ala8]angiotensin II (0.03-1 mg/kg i.v.) induced, at least at high doses, a non-parallel shift to the right of the angiotensin II dose-response curve and this was associated with a reduction of the maximal response. During a 70 min period, the effect of [Sar1,Val5,Ala8]angiotensin II (1 mg/kg i.v.) on the angiotensin II (0.3 microgram/kg i.v.)-induced pressor response was shown to be reversible, the effect of SR 47155A (10 mg/kg i.v.) was partially reversible and the effect of SR 47436 (3 mg/kg i.v.), EXP 3174 (1 mg/kg i.v.) or losartan (6 mg/kg i.v.) was not reversed at the end of this 70 min period. Administration of SR 47155A (10 mg/kg i.v.) before SR 47436 (1-10 mg/kg i.v.) reversed the reduced angiotensin II-maximal response induced by SR 47436. Administration of SR 47436 (10 mg/kg i.v.) before SR 47155A (1-10 mg/kg i.v.) prevented the full development of the pressor response as observed in the absence of SR 47436. In the pithed rat, SR 47436 (30 mg/kg i.v.) and losartan (30 mg/kg i.v.) reduced the change in diastolic blood pressure induced by electrical stimulation of the spinal cord only at low stimulation rates. Taken together these results indicate that SR 47436, under in vivo conditions, is a potent non-peptide angiotensin receptor antagonist. The type of antagonism (partially insurmountable but selective) can be explained by different theoretical models which are discussed.
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
March 1986,
The Journal of physiology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
June 1968,
Archives internationales de pharmacodynamie et de therapie,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
July 1996,
Journal of cardiovascular pharmacology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
December 1988,
British journal of pharmacology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
January 1988,
Pharmacology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
January 2002,
Pharmacology, biochemistry, and behavior,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
February 1969,
British journal of pharmacology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
June 1993,
Naunyn-Schmiedeberg's archives of pharmacology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
January 1988,
The American journal of physiology,
B Christophe, and
R Libon, and
C Cazaubon, and
D Nisato, and
A Manning, and
P Chatelain
January 2009,
Proceedings of the Western Pharmacology Society,
